Zai Lab Ltd ADR Repr 1 Shs ZLAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ZLAB is a good fit for your portfolio.
News
-
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
-
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
-
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
-
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
-
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
-
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
-
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
-
Zai Lab Announces Participation in March Investor Conference
Trading Information
- Previous Close Price
- $14.22
- Day Range
- $13.93–14.23
- 52-Week Range
- $13.48–39.50
- Bid/Ask
- $14.07 / $14.08
- Market Cap
- $1.40 Bil
- Volume/Avg
- 465,965 / 677,467
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.15
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 2,175
- Website
- https://www.zailaboratory.com
Comparables
Valuation
Metric
|
ZLAB
|
APLM
|
02105
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.74 | 2.54 | 2.46 |
Price/Sales | 5.15 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
ZLAB
|
APLM
|
02105
|
---|---|---|---|
Quick Ratio | 4.29 | 2.82 | 9.91 |
Current Ratio | 4.63 | 2.95 | 9.98 |
Interest Coverage | — | −1,154.63 | −447.63 |
Quick Ratio
ZLAB
APLM
02105
Profitability
Metric
|
ZLAB
|
APLM
|
02105
|
---|---|---|---|
Return on Assets (Normalized) | −22.36% | −123.31% | −48.47% |
Return on Equity (Normalized) | −26.78% | — | — |
Return on Invested Capital (Normalized) | −30.45% | — | — |
Return on Assets
ZLAB
APLM
02105
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vxcxtsxfj | Jlpx | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wlzvccjyk | Xmpgl | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kfbnsvlg | Ccysqlm | $98.1 Bil | |
MRNA
| Moderna Inc | Yytyppl | Djh | $39.1 Bil | |
ARGX
| argenx SE ADR | Wmsnnfwkv | Wrkb | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Vlwjybnf | Vrjv | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xcrgrvcv | Clwlmv | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mkfprwyx | Zmktfw | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xnkxlqdm | Mwbtmmz | $12.5 Bil | |
INCY
| Incyte Corp | Msdjrgw | Tfwdsf | $11.9 Bil |